clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.
norfloxacino
laboratÓrio globo sa - norfloxacino - antibioticos sistemicos simples
norfloxacino
pharmascience indÚstria farmacÊutica ltda - norfloxacino - antibioticos sistemicos simples
norfloxacino
sandoz do brasil indÚstria farmacÊutica ltda - norfloxacino - antibioticos sistemicos simples
norfloxacino
uniÃo quÍmica farmacÊutica nacional s/a - norfloxacino - antibioticos sistemicos simples
norfloxacino
brainfarma indÚstria quÍmica e farmacÊutica s.a - norfloxacino - antibioticos sistemicos simples
norfloxacino
ems s/a - norfloxacino - antibioticos sistemicos simples
norfloxacino
laboratÓrio teuto brasileiro s/a - norfloxacino - antibioticos sistemicos simples
norfloxacino
nova quimica farmacÊutica s/a - norfloxacino - antibioticos sistemicos simples
norfloxacino
sanofi medley farmacÊutica ltda. - norfloxacino - antibioticos sistemicos simples